Literature DB >> 20814349

Analytical toxicology of emerging drugs of abuse.

Frank T Peters1, Jorge A Martinez-Ramirez.   

Abstract

The emergence of ever new drugs of abuse on the illicit drug market is an ongoing challenge for analytical toxicologists. Because most of these new drugs or drug classes are not detected by established analytical methods targeting classic drugs of abuse, analytical procedures must be adapted or new procedures must be developed to cover these new compounds. This review summarizes the analytical toxicology of the following classes of emerging drugs of abuse: piperazines, phenethylamines (2Cs and FLYs), 4-substituted amphetamines, β-keto-amphetamines, 2,5-dimethoxy-amphetamines, pyrrolidinophenones, and synthetic cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20814349     DOI: 10.1097/FTD.0b013e3181f33411

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens.

Authors:  Fessessework Guale; Shahriar Shahreza; Jeffrey P Walterscheid; Hsin-Hung Chen; Crystal Arndt; Anna T Kelly; Ashraf Mozayani
Journal:  J Anal Toxicol       Date:  2012-11-01       Impact factor: 3.367

2.  Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.

Authors:  Matthew D Krasowski; Sean Ekins
Journal:  J Cheminform       Date:  2014-05-10       Impact factor: 5.514

3.  Use of novel psychoactive substances by inpatients on general adult psychiatric wards.

Authors:  Jack L Stanley; Daniel V Mogford; Rebecca J Lawrence; Stephen M Lawrie
Journal:  BMJ Open       Date:  2016-05-10       Impact factor: 2.692

4.  High-Throughput Qualitative and Quantitative Drug Checking by MALDI HRMS.

Authors:  Timothée Joye; Christèle Widmer; Roxane Morger Mégevand; Serge Longère; Marc Augsburger; Aurélien Thomas
Journal:  Front Chem       Date:  2020-08-25       Impact factor: 5.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.